Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13394063 | 0.89 | PIK3CD (0.41) | ADORA2AADORA1YTHDC1PIK3CD | |
| SCHEMBL13394072 | 0.89 | ADORA2A (0.41) | ADORA2AADORA1PIK3CDPI4KAPI4K2B | |
| SCHEMBL12112236 | 0.82 | PIK3CD (0.47) | ADORA2AADORA1PIK3CD | |
| SCHEMBL12112208 | 0.81 | MAPK1 (0.43) | SLC29A1ADORA2AADORA1YTHDC1PIK3CD | |
| SCHEMBL12112225 | 0.81 | PDE4A (0.48) | SLC29A1ADORA2AADORA1PIK3CDPI4KA | |
| SCHEMBL12112239 | 0.81 | MEN1 (0.41) | ADORA2AYTHDC1PIK3CDPI4KAPI4K2B | |
| SCHEMBL12112250 | 0.81 | PIK3CD (0.37) | ADORA2APIK3CDPI4KAPI4K2BPI4K2A | |
| SCHEMBL12112229 | 0.81 | SLC29A1 (0.43) | SLC29A1ADORA2APIK3CDPI4KAPI4K2B | |
| SCHEMBL12112232 | 0.81 | PIK3CD (0.39) | ADORA2APIK3CDPI4KAPI4K2BPI4K2A | |
| SCHEMBL13394115 | 0.81 | PIK3CD (0.41) | ADORA2AADORA1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2014149084-A2 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | HOSMANE, RAMACHANDRA S. | 2011-11-10 | — | — | US | disclosed |
| WO-2010039187-A2 | FUSED DIIMIDAZODIAZEPINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | SLC29A1 2701/4885ADORA2A 4578/4885ADORA1 4375/4885 |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | IKZF3, AADAC, IKBKE | SLC29A1 3265/4885ADORA2A 2862/4885ADORA1 3039/4885 |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | SLC29A1 2701/4885ADORA2A 4578/4885ADORA1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.